Skip to main content
Top
Published in: Rheumatology International 11/2020

01-11-2020 | Rheumatoid Arthritis | Systematic review

Association of rheumatoid arthritis with hearing loss: a systematic review and meta-analysis

Authors: Nikolaos Chaitidis, Patroklos Theocharis, Charalampos Festas, Ioanna Aritzi

Published in: Rheumatology International | Issue 11/2020

Login to get access

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease affecting up to 1% of the worldwide population. RA is associated with multiple extra-articular manifestations (EAMs). Middle ear, cochlea and the auditory nerve are suspected sites of RA activity and hearing loss is a possible novel EAM of RA. Objective was to investigate the association of RA with the different subtypes of hearing loss. This systematic review was performed according to the PRISMA guidelines. A random effects model meta-analysis was conducted and the I2 was used to assess heterogeneity. Twelve studies comprising 20,022 RA patients and 79,244 controls were included in this systematic review. All studies were observational and were rated to a moderate rate of bias. RA patients had nearly fourfold increased odds of sensorineural hearing loss (SNHL) compared with controls (OR 3.42; 95% CI 2.50–4.69; I2 = 13). RA patients also had a significantly increased risk of SNHL (RR 2.28; 95% CI 1.88–2.76; I2 = 0). RA patients did not have increased odds of conductive hearing loss (CHL) and mixed hearing loss (MHL) (OR 1.36; 95% CI 0.52–3.55; I2 = 22); (OR 2.73; 95% CI 0.78–9.58; I2 = 0%). RA is significantly associated with SNHL. RA is not associated with CHL and MHL. Early screening of RA patients with pure tone audiometry should be considered.
Literature
16.
go back to reference Shamseer L, Moher D, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350:g7647CrossRef Shamseer L, Moher D, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350:g7647CrossRef
18.
go back to reference Sterne JA, Hernan MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919CrossRef Sterne JA, Hernan MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919CrossRef
20.
go back to reference The Cochrane Collaboration (2014) Review manager (RevMan) [computer program]. Version 5.3. The Nordic Cochrane Centre, Copenhagen The Cochrane Collaboration (2014) Review manager (RevMan) [computer program]. Version 5.3. The Nordic Cochrane Centre, Copenhagen
21.
go back to reference Garcia Callejo FJ, Conill Tobias N, Munoz Fernandez N et al (2007) Hearing impairment in patients with rheumatoid arthritis. Acta Otorrinolaringol Esp 58:232–238CrossRef Garcia Callejo FJ, Conill Tobias N, Munoz Fernandez N et al (2007) Hearing impairment in patients with rheumatoid arthritis. Acta Otorrinolaringol Esp 58:232–238CrossRef
30.
41.
go back to reference Magaro M, Zoli A, Altomonte L et al (1990) Sensorineural hearing loss in rheumatoid arthritis. Clin Exp Rheumatol 8:487–490PubMed Magaro M, Zoli A, Altomonte L et al (1990) Sensorineural hearing loss in rheumatoid arthritis. Clin Exp Rheumatol 8:487–490PubMed
Metadata
Title
Association of rheumatoid arthritis with hearing loss: a systematic review and meta-analysis
Authors
Nikolaos Chaitidis
Patroklos Theocharis
Charalampos Festas
Ioanna Aritzi
Publication date
01-11-2020
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 11/2020
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04609-1

Other articles of this Issue 11/2020

Rheumatology International 11/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.